Catalog No.
DHK06406
Expression system
Mammalian cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa (CLC)
Target
Bispecific, Drosophila Delta homolog 3, Delta3, Delta-like protein 3, DLL3, Leukocyte surface antigen CD47, CD47, Antigenic surface determinant protein OA3, IAP, Integrin-associated protein, Protein MER6, MER6
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9NYJ7 & Q08722
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
PT-217, PT 217, PT217
Clone ID
PT-217
Erratum to 'Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors?' [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100796]., PMID:40534996
The next generation of immunotherapies for lung cancers., PMID:40528044
T-Cell Engager Therapy in Prostate Cancer: Molecular Insights into a New Frontier in Immunotherapy., PMID:40507301
OGDHL regulates nucleotide metabolism, tumor growth, and neuroendocrine marker expression in prostate cancer., PMID:40502162
Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer., PMID:40496850
Chitosan gold nanogel containing Rova-Typhoid immunotoxins against the DLL3 receptor has a promising effect on small-cell lung cancer., PMID:40455231
Treatment of small cell lung cancer; advances and future prospects., PMID:40446464
Taking a Bite Out of Small Cell Lung Cancer By Leveraging Precision-Directed Delta-Like Ligand-3 Therapies., PMID:40440602
The Path To Tarlatamab Approval: Leveraging Innovative Strategies and Global Regulatory Pathways., PMID:40419854
FOXA2 promotes metastatic competence in small cell lung cancer., PMID:40419484
Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors., PMID:40370549
Molecular Subtypes and Targeted Therapeutic Strategies in Small Cell Lung Cancer: Advances, Challenges, and Future Perspectives., PMID:40333678
Functional characterization of the ATOH1 molecular subtype indicates a pro-metastatic role in small cell lung cancer., PMID:40305287
Extracellular Vesicular Delta-Like Ligand 3 and Subtype Transcription Factors for Small Cell Lung Cancer Diagnosis., PMID:40285610
Targeting DLL3: Innovative Strategies for Tumor Treatment., PMID:40284515
Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases., PMID:40280845
Population Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer., PMID:40261494
Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review., PMID:40260055
Real-world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma., PMID:40247437
Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors?, PMID:40225957
Challenges of small cell lung cancer heterogeneity and phenotypic plasticity., PMID:40211072
Comparison of two immunotoxins against DLL3 receptor; as an inhibitor for small cell lung cancer., PMID:40177519
Targeting the tumour cell surface in advanced prostate cancer., PMID:40169837
Infectious Complications in Patients Treated with T-cell Engagers as Cancer Immunotherapies, A Descriptive Study from the REISAMIC Registry., PMID:40165410
Advances in adoptive cell therapies in small cell lung cancer., PMID:40160238
[New perspectives in the management of small cell bronchial cancer]., PMID:40155069
DLL3 Expression in Neuroendocrine Carcinomas and Neuroendocrine Tumours: Insights From a Multicentric Cohort of 1294 Pulmonary and Extrapulmonary Neuroendocrine Neoplasms., PMID:40153138
State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer., PMID:40112242
Safety and efficacy outcomes of delta‑like ligand 3 inhibitors for the treatment of solid tumors: A systematic review and single‑arm meta‑analysis., PMID:40110579
Comparative profiling of surgically resected primary tumors and their lymph node metastases in small-cell lung cancer., PMID:40107154
Current and future perspectives in extensive-stage small-cell lung cancer., PMID:40093978
Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review., PMID:40083373
Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer., PMID:40075480
Engineered exosomes restore miR-508-5p expression in uterine corpus endometrial carcinoma and reduce tumor progression and metastasis by targeting DLL3., PMID:40066092
Reviewing the Genetic and Molecular Foundations of Congenital Spinal Deformities: Implications for Classification and Diagnosis., PMID:40004644
Notch signaling pathway in osteogenesis, bone development, metabolism, and diseases., PMID:39985304
Prenatal diagnosis and pregnancy outcomes in fetuses with vertebral abnormalities., PMID:39978942
[Aggressive variant prostate cancer and transdifferentiated neuroendocrine prostate cancer: from diagnosis to therapy]., PMID:39928109
Advancement Opportunities and Endeavor of Innovative Targeted Therapies for Small Cell Lung Cancer., PMID:39897044
Tarlatamab and the Future of Immunotherapy: A New Approach to Small Cell Lung Cancer., PMID:39877675
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer., PMID:39876075
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting., PMID:39874041
Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms and its potential diagnostic value., PMID:39865119
Recent Advances in the Clinical Translation of Small-Cell Lung Cancer Therapeutics., PMID:39858036
Methylation status of selected genes in non-small cell lung carcinoma - current knowledge and future perspectives., PMID:39832203
Molecular and Immunohistochemical Classification of Extrapulmonary Small Cell Neuroendocrine Carcinomas: A Study of 181 Cases., PMID:39826683
DLL3 draws two antibody-drug conjugate deals., PMID:39806012
Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors., PMID:39802817
The analysis of molecular classification of pulmonary neuroendocrine tumors and relationship between YAP1 and efficacy., PMID:39786663
New developments in immunotherapy for SCLC., PMID:39762075
For research use only. Not for human or drug use.
